Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus

被引：10

作者：

Adinolfi, Luigi Elio ^{[1
]}

Jacobson, Ira ^{[2
]}

Bondin, Mark ^{[3
]}

Cacoub, Patrice ^{[4
,5
,6
,7
,8
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Dept Med Surg Neurol Metab & Geriatr Sci, Naples, Italy

[2] NYU Langone Hlth, New York, NY USA

[3] AbbVie Inc, Chicago, IL USA

[4] UPMC Univ Paris 06, Sorbonne Univ, UMR 7211, Paris, France

[5] UPMC Univ Paris 06, Sorbonne Univ, Inflammat Immunopathol Biotherapy Dept DHU i2B, Paris, France

[6] INSERM, UMR S 959, Paris, France

[7] CNRS, FRE3632, Paris, France

[8] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, Paris, France

来源：

ANTIVIRAL THERAPY | 2018年 / 23卷

关键词：

HEPATITIS-C VIRUS; SUSTAINED VIROLOGICAL RESPONSE; INSULIN-RESISTANCE; HEPATOCELLULAR-CARCINOMA; INCREASED RISK; EXTRAHEPATIC MANIFESTATIONS; GENOTYPE DISTRIBUTION; ANTIVIRAL TREATMENT; ADVANCED FIBROSIS; GLYCEMIC CONTROL;

D O I：

10.3851/IMP3255

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Type 2 diabetes mellitus (T2DM) has been identified as an extrahepatic manifestation of chronic HCV infection. Conversely, in the context of chronic HCV infection, T2DM can accelerate the course of HCV-induced liver disease leading to increased risk of fibrosis, cirrhosis and hepa-tocellular carcinoma. The presence of T2DM negatively impacts the efficacy of interferon-based antiviral therapy, but real-world data with high-efficacy direct-acting antiviral therapies suggest high viral clearance rates in T2DM patients. In HCV-infected individuals, viral eradication is associated with a reduced risk of de novo T2DM in non-diabetic patients and beneficial metabolic changes in patients with T2DM, highlighting the importance of antiviral treatment and physician awareness of this association.

引用

页码：11 / 21

页数：11

共 50 条

[1] Expert Opinion on Managing Chronic HCV in Patients with Neuropsychiatric Manifestations
Forton, Daniel
Weissenborn, Karin
Bondin, Mark
Cacoub, Patrice
ANTIVIRAL THERAPY, 2018, 23 : 47 - 55
[2] Expert Opinion on Managing Chronic HCV in Patients with Cardiovascular Disease
Vassalle, Cristina
Petta, Salvatore
Pepe, Alessia
Craxi, Antonio
Bondin, Mark
Cacoub, Patrice
ANTIVIRAL THERAPY, 2018, 23 : 35 - 46
[3] PREVALENCE OF CHRONIC HCV INFECTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN RUSSIA
Beliy, Petr A.
Dudina, Kristina R.
Znoyko, Olga O.
Markova, Tatyana N.
Morozova, Irina A.
Blokhina, Natalia P.
Nurmukhametova, Elena A.
Yushchuk, Nikolay D.
DIABETES MELLITUS, 2022, 25 (01): : 4 - 13
[4] Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis
Zignego, Anna Linda
Pawlotsky, Jean-Michel
Bondin, Mark
Cacoub, Patrice
ANTIVIRAL THERAPY, 2018, 23 : 1 - 9
[5] An Expert Opinion on the Management of Type 2 Diabetes Mellitus in Children and Adolescents
Rajput, Rajesh
Jha, Sujeet
Panda, Jayanta Kumar
Subrahmanyam, Appalavenkata Kandregula
Das, Sambit
JOURNAL OF DIABETOLOGY, 2021, 12 (04) : 424 - 433
[6] Expert Opinion on the Management of Renal Manifestations of Chronic HCV Infection
Fabrizi, Fabrizio
Negro, Francesco
Bondin, Mark
Cacoub, Patrice
ANTIVIRAL THERAPY, 2018, 23 : 57 - 67
[7] INTERLINK BETWEEN HCV INFECTION AND GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
Riaz, Sana
Abbas, Amir
Shirin, Aiman
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (01): : 1963 - 1969
[8] Managing hypertension in patients with type 2 diabetes mellitus
Dobesh, Paul P.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (12) : 1140 - 1149
[9] Expert Opinion on Managing Chronic HCV in Patients with Non-Hodgkin Lymphoma and other Extrahepatic Malignancies
Ferri, Clodoveo
Feld, Jordan J.
Bondin, Mark
Cacoub, Patrice
ANTIVIRAL THERAPY, 2018, 23 : 23 - 33
[10] Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy
Donadon, V.
Balbi, M.
Dal Mas, M.
Casarin, P.
Zanette, G.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A44 - A44

← 1 2 3 4 5 →